Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USB005 Safety and PK in Healthy Volunteers
NCT03615196Phase 1Completed
- Sponsor
- US Biotest, Inc.
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aclerastide in corneal injury (5 arms), sponsored by US Biotest, Inc. Primary endpoints: Percentage of volunteers with dose limiting toxicities at 36 days, Percentage of volunteers with ocular adverse events at 36 days and 2 more. Started Jul 2018; status: completed.
02
Drugs
aclerastide
03
Conditions
corneal injury
Beyond the preview
Go deeper on NCT03615196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615196.